BPC-157 (Oral) vs Phosphate Buffered Saline
A side-by-side research comparison of BPC-157 (Oral) and Phosphate Buffered Saline across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | BPC-157 (Oral) | Phosphate Buffered Saline |
|---|---|---|
| Full name | BPC-157 Oral Formulation (Arginate Salt) | Phosphate Buffered Saline (PBS) |
| Category | Healing & Recovery | Healing & Recovery |
| Status | Research compound | Buffer solvent |
| Mechanism | Same mechanism as injectable BPC-157 but delivered orally. Upregulates VEGF, modulates NO system, and promotes gut mucosal healing through direct contact and systemic absorption. | The phosphate buffer maintains a stable, near-physiological pH (~7.4) while the saline provides isotonic conditions, protecting peptides and proteins from pH-driven degradation during dissolution and handling. |
| Molecular weight | 1419.53 Da | Buffered salt solution |
| Half-life | ~4 hours (oral bioavailability lower but sustained) | N/A (solvent) |
| Bioavailability | ~40-60% oral (arginate salt form) | N/A (diluent) |
| Typical dose | 500 mcg - 1 mg | Volume to reach target concentration |
| Frequency | 1-2x daily | As needed to reconstitute |
| Route | Oral capsule (arginate salt) | Added to peptide/protein vial |
BPC-157 (Oral) reported benefits
- Gut healing (direct contact)
- Liver protection
- Oral convenience
- Systemic anti-inflammatory
- No injection required
Phosphate Buffered Saline reported benefits
- Maintains stable physiological pH
- Isotonic and gentle on peptides/proteins
- Neutral research-grade diluent
Related comparisons
Research and educational reference only. Not medical advice.